pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
Vera Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 0
- Drugs
- 18
- Patents
- 7
Vera Therapeutics patents
7 pharmaceutical patents indexed for Vera Therapeutics. 0 expire within 24 months.
Vera Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12201639
Aqueous oral pharmaceutical suspension compositions
granted -
US 11873296
Solid forms of a dual RAF/MEK inhibitor
granted -
US 11833159
Non-hormonal steroid modulators of NF-kB for treatment of disease
granted -
US 11690853
Non-hormonal steroid modulators of NF-κβ for treatment of disease
granted -
US 11471471
Aqueous oral pharmaceutical suspension compositions
granted -
US 11382922
Aqueous oral pharmaceutical suspension compositions
granted -
US 10857161
Non-hormonal steroid modulators of NF-kB for treatment of disease
granted
Frequently asked questions
How many patents does Vera Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vera Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.